Spero Therapeutics (NASDAQ:SPRO) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.94 and traded as low as $1.1650. Spero Therapeutics shares last traded at $1.18, with a volume of 414,066 shares traded.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Compass Point upgraded shares of Spero Therapeutics to a “neutral” rating in a research report on Monday, September 14th. Zacks Research raised shares of Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. HC Wainwright raised their target price on shares of Spero Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Monday, September 14th. Finally, Weiss Ratings upgraded shares of Spero Therapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 12th. One research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $6.00.

Spero Therapeutics Trading Down 2.6%

The company has a market capitalization of $65.23 million, a price-to-earnings ratio of 10.18 and a beta of 1.50. The company’s 50 day simple moving average is $1.20 and its 200-day simple moving average is $1.94.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. Sell-side analysts anticipate that Spero Therapeutics, Inc. will post -0.58 EPS for the current year.

Institutional Trading of Spero Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SPRO. Alphabet Inc. acquired a new position in Spero Therapeutics in the 2nd quarter valued at $1,967,000. BlackRock Inc. acquired a new stake in shares of Spero Therapeutics during the second quarter worth $1,314,000. GSA Capital Partners LLP acquired a new stake in shares of Spero Therapeutics during the second quarter worth $632,000. Intrepid Family Office LLC boosted its holdings in shares of Spero Therapeutics by 50.0% during the fourth quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock worth $384,000 after purchasing an additional 55,000 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in shares of Spero Therapeutics during the second quarter worth $55,000. 25.60% of the stock is owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious bacterial infections and other infectious diseases. The company’s research programs are aimed at addressing drug-resistant pathogens and conditions for which existing therapies may be limited.

Spero’s pipeline has included tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic being developed for complicated urinary tract infections, including pyelonephritis.